ZALCITABINE - Generic Drug Details

What are the generic drug sources for zalcitabine and what is the scope of patent protection?

Zalcitabine is the generic ingredient in one branded drug marketed by Roche and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for ZALCITABINE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	116
Clinical Trials:	49
DailyMed Link:	ZALCITABINE at DailyMed

Recent Clinical Trials for ZALCITABINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Avexa	Phase 3
PENTA Foundation	Phase 2/Phase 3
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2/Phase 3

See all ZALCITABINE clinical trials

Medical Subject Heading (MeSH) Categories for ZALCITABINE

Anti-HIV Agents

Antimetabolites

Reverse Transcriptase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ZALCITABINE

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for ZALCITABINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-002	Jun 19, 1992		DISCN	No	No
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-001	Jun 19, 1992		DISCN	No	No

Expired US Patents for ZALCITABINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-001	Jun 19, 1992
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-002	Jun 19, 1992
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-002	Jun 19, 1992
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-001	Jun 19, 1992

Zalcitabine Market Dynamics, Financial Trajectory, Patent Status, and Generic Entry Risk

Last updated: September 7, 2026

Zalcitabine, marketed as Hivid by Hoffmann-La Roche, was an early nucleoside reverse transcriptase inhibitor approved for HIV-1 treatment in 1992. Its commercial position deteriorated as combination antiretroviral therapy replaced nucleoside monotherapy and better-tolerated agents entered the market. Roche discontinued Hivid in the United States in 2006. Zalcitabine has no meaningful current commercial market, no active U.S. exclusivity, and no material biosimilar risk because it is a small-molecule drug rather than a biologic.

The drug’s financial trajectory followed the broader HIV treatment transition: initial value as one of the few approved antiretrovirals, followed by rapid erosion after the introduction of combination regimens, lamivudine, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and later single-tablet therapies.

What is zalcitabine and how was it used?

Zalcitabine, also known as 2',3'-dideoxycytidine or ddC, is a cytidine analogue that inhibits HIV reverse transcriptase after intracellular conversion to its active triphosphate form. It was administered orally, generally three times daily, and was used with other antiretroviral agents.

Attribute	Zalcitabine
Generic name	Zalcitabine
Development code	ddC
Brand	Hivid
Original sponsor	Hoffmann-La Roche
Drug class	Nucleoside reverse transcriptase inhibitor
FDA approval	1992
Original indication	HIV-1 infection
Dosage forms	0.375 mg and 0.75 mg tablets
Administration	Oral, three times daily
Current U.S. status	Discontinued
Biologic status	Small molecule, not a biologic
Current guideline role	None

The original FDA label authorized Hivid for use in combination with other antiretroviral agents. Zalcitabine was not positioned as a modern stand-alone treatment because monotherapy rapidly produced resistance and was clinically inferior to combination therapy.

When did zalcitabine lose exclusivity?

Zalcitabine lost practical exclusivity during the 1990s as its principal commercial value shifted from a branded HIV product to a replaceable component of combination therapy. Roche discontinued Hivid in the United States in 2006 after the drug had become clinically obsolete.

The precise U.S. patent expiration date is less commercially relevant than the product’s regulatory and clinical obsolescence. Hivid’s market had largely collapsed before patent protection could generate meaningful late-life value. The product’s value was reduced by:

• Expansion of combination antiretroviral therapy.
• Availability of better-tolerated NRTIs.
• Frequent dosing.
• Peripheral neuropathy and pancreatitis risks.
• Limited use in treatment guidelines.
• Declining demand from infectious-disease specialists.
• Availability of newer fixed-dose combinations.

The FDA lists Hivid among discontinued products and did not identify the discontinuation as a withdrawal based on safety or effectiveness concerns. The commercial discontinuation reflected the availability of superior treatment alternatives and low demand rather than a conventional patent cliff alone (U.S. Food and Drug Administration [FDA], n.d.-a).

What patents protected zalcitabine?

Zalcitabine was protected historically through compound, pharmaceutical composition, and HIV-treatment patent claims associated with the discovery and development of nucleoside analogues. Those rights no longer create a material commercial barrier.

Publicly available current FDA materials do not identify any active Orange Book patent protection for a marketed zalcitabine product. The relevant economic conclusion is clear:

Patent issue	Current commercial position
Active U.S. compound exclusivity	None of commercial significance
Active Orange Book protection	None associated with an available marketed Hivid product
Formulation patent barrier	No meaningful current barrier
Method-of-use protection	Expired or commercially irrelevant
Manufacturing patent barrier	No material barrier for a competent generic manufacturer
Patent litigation risk	Negligible
Paragraph IV risk	No active branded product against which a meaningful challenge would be filed

Historical patent records may include broad nucleoside analogue and antiviral claims rather than a single commercially decisive “zalcitabine patent.” The drug’s current status does not depend on resolving those historical patent families because the product has no active U.S. commercial franchise.

What is the Orange Book status of Hivid?

Hivid was previously listed as a prescription drug product under Roche’s NDA. The relevant product presentations were 0.375 mg and 0.75 mg tablets. The product is no longer an active commercial reference product in the United States.

An Orange Book listing would have mattered during the period when Roche marketed Hivid and a generic applicant sought approval under an abbreviated new drug application. Today, the practical issues are different:

1. Hivid is not an active branded growth product.
2. No current U.S. market exists that would support a conventional Paragraph IV strategy.
3. Any generic applicant would face a demand problem rather than a patent problem.
4. A dormant or discontinued reference product could require a regulatory pathway different from a standard competitive launch against an actively marketed brand.

The FDA’s discontinued-drug framework also affects the interpretation of regulatory status. Commercial discontinuation does not automatically mean that the FDA withdrew the product for safety or efficacy reasons (FDA, n.d.-a).

How did clinical limitations affect zalcitabine sales?

Clinical toxicity was a central factor in the decline of zalcitabine. The product label identified peripheral neuropathy, pancreatitis, oral ulceration, and other adverse effects. These liabilities became less acceptable as physicians gained access to more tolerable NRTIs and more effective combination regimens.

Zalcitabine also had unfavorable treatment characteristics:

• Three-times-daily dosing.
• Narrower clinical utility than later NRTIs.
• Significant mitochondrial toxicity concerns associated with early nucleoside analogues.
• Resistance when used without an effective combination partner.
• Limited use in patients with prior antiretroviral exposure.
• Lack of a role in contemporary first-line therapy.

By the late 1990s, HIV treatment had moved toward highly active antiretroviral therapy using combinations of two NRTIs with a protease inhibitor or an NNRTI. Zalcitabine was increasingly displaced by lamivudine, zidovudine, stavudine, didanosine, abacavir, and tenofovir, depending on the treatment period.

How did zalcitabine compare with competing HIV drugs?

Drug	Company or principal originator	Historical advantage over zalcitabine	Long-term outcome
Zidovudine	Burroughs Wellcome, later GlaxoSmithKline	Earlier approval and broader use	Retained historical importance but declined
Didanosine	Bristol-Myers Squibb	Alternative NRTI positioning	Later discontinued in many markets
Stavudine	Bristol-Myers Squibb	Widely used in early combination therapy	Declined because of toxicity
Lamivudine	Glaxo Wellcome	Better tolerability and convenient dosing	Became a durable backbone agent
Abacavir	GlaxoSmithKline	Stronger combination utility	Retained use with safety screening
Tenofovir	Gilead Sciences	Improved durability and once-daily use	Became a major backbone agent
Zalcitabine	Roche	Early NRTI availability	Commercially discontinued

Lamivudine was particularly damaging to zalcitabine’s position. It offered a more convenient dosing profile, stronger combination-treatment utility, and a more favorable tolerability profile. Tenofovir later accelerated the decline of older NRTIs by supporting once-daily regimens and fixed-dose combinations.

What was zalcitabine’s financial trajectory?

Roche did not report Hivid revenue as a separately disclosed material product in its public financial reporting. That limits any defensible estimate of peak sales, cumulative revenue, or product-level profit. The available financial conclusion is directional rather than a precise revenue series.

Commercial phases

Period	Market phase	Financial effect
1992-1995	Early antiretroviral adoption	Initial revenue growth from limited treatment alternatives
1996-1999	Combination therapy expansion	Share loss to newer NRTIs and multi-drug regimens
2000-2004	Mature decline	Low and shrinking demand; reduced strategic importance
2005-2006	End-of-life phase	Commercial discontinuation and negligible franchise value
After 2006	No active U.S. franchise	No meaningful Roche revenue exposure

Zalcitabine’s financial value was likely concentrated in the early-to-mid 1990s, when the HIV market was expanding and the number of effective antiretroviral options was small. The drug did not maintain value into the modern HIV market because clinical differentiation disappeared.

Roche’s larger pharmaceutical portfolio also reduced the strategic importance of Hivid. Unlike a blockbuster with continuing demand, Hivid had limited ability to support pricing, lifecycle management, or combination-product development.

What licensing deals affected zalcitabine?

No major current licensing transaction has commercial relevance for zalcitabine. The product was developed and marketed by Hoffmann-La Roche, but its value did not evolve into a significant platform, co-formulation, or successor product franchise.

The principal strategic activity surrounding zalcitabine was competitive displacement rather than licensing. HIV companies concentrated on:

• Better-tolerated NRTIs.
• Protease inhibitors.
• NNRTIs.
• Fixed-dose combinations.
• Once-daily administration.
• Reduced pill burden.
• Improved resistance profiles.

Zalcitabine did not become the anchor for a durable combination product. That limited its licensing value and prevented Roche from extending the product lifecycle through a differentiated delivery system or reformulated regimen.

What generic entry risks exist for zalcitabine?

Current generic entry risk is low in economic terms because the reference product is no longer actively marketed. A generic manufacturer could face limited patent risk, but it would also face limited demand and uncertain reimbursement.

Regulatory risk

A prospective applicant would need to address:

• Availability and suitability of the reference product for an abbreviated application.
• Bioequivalence to the relevant tablet strength.
• Product stability and manufacturing controls.
• Market access after approval.
• Whether sufficient clinical demand remains.
• Procurement by public-health programs or specialized markets.

Commercial risk

The main barrier is not intellectual property. It is market size. A generic zalcitabine product would compete against established, guideline-supported therapies with better tolerability and simpler dosing. Hospitals and HIV clinics generally have little incentive to substitute a discontinued early-generation NRTI for modern alternatives.

A low-cost manufacturer might identify limited demand in specific international markets, but such a strategy would depend on local registration, procurement practices, treatment guidelines, and availability of alternative antiretrovirals.

Is there biosimilar risk for zalcitabine?

No. Zalcitabine is a chemically synthesized small molecule. It is subject to generic-drug principles, not the biosimilar pathway under the Public Health Service Act.

The relevant competitive risks are:

• Generic substitution.
• International copies.
• Unlicensed or limited-market manufacture.
• Therapeutic replacement by newer antiretrovirals.

No biosimilar developer, biologics interchangeability issue, or biologic manufacturing barrier is relevant.

Which companies are challenging zalcitabine?

No active company-led patent challenge has material commercial significance. During the product’s market life, competition came primarily from other antiretroviral manufacturers, including Glaxo Wellcome, Bristol-Myers Squibb, and Gilead Sciences.

The competitive threat was therapeutic rather than litigation-driven. Companies displaced zalcitabine by offering products with:

• Less frequent dosing.
• Better toxicity profiles.
• Stronger resistance management.
• Greater compatibility with combination regimens.
• More effective commercial lifecycle management.

There is no meaningful current Paragraph IV litigation or settlement agreement affecting zalcitabine.

What manufacturing and geographic barriers remain?

Zalcitabine synthesis is not generally viewed as a major manufacturing barrier for an experienced pharmaceutical company. The product is a small molecule and does not require biologic cell culture, specialized cold-chain logistics, or complex device technology.

The practical barriers are market-specific:

Geography	Current commercial outlook
United States	No meaningful branded market; discontinued product
European markets	Limited or absent modern treatment role
Emerging markets	Possible historical or niche demand, subject to local registration
Public-health procurement	Low priority compared with current guideline drugs
Unregulated markets	Potential substitution risk, but limited visibility and quality control

Modern manufacturing capability does not create a corresponding commercial opportunity. Demand is constrained by treatment guidelines and physician preference for newer agents.

What is the current litigation and settlement status?

There is no material active patent litigation, Paragraph IV settlement, or branded-generic dispute associated with zalcitabine in the current market. The product’s U.S. commercial discontinuation occurred years ago, and its patent estate no longer supports litigation-driven value.

The absence of litigation should not be interpreted as a sign of strong patent protection. It reflects the opposite commercial condition: little revenue remains to defend.

How strong is the zalcitabine patent estate?

The current patent estate is commercially weak.

Factor	Assessment
Patent duration	Expired or no longer commercially relevant
Claim breadth	Historical claims may have been broad, but no current blocking value
Orange Book leverage	None of practical significance
Formulation protection	No current market defense
Method-of-use protection	No material modern treatment use
Manufacturing protection	No meaningful barrier
Litigation leverage	Minimal
Lifecycle-management potential	Exhausted

Zalcitabine’s remaining intellectual-property value is archival rather than strategic. It may be relevant to historical patent research, freedom-to-operate analysis for nucleoside analogues, or pharmaceutical development history, but not to current revenue protection.

Key Takeaways

• Zalcitabine was an early Roche NRTI marketed as Hivid and approved by the FDA in 1992.
• Its market declined as combination therapy, lamivudine, tenofovir, abacavir, protease inhibitors, and fixed-dose regimens gained adoption.
• Roche discontinued Hivid in the United States in 2006.
• Product-level revenue was not separately disclosed by Roche, preventing a reliable standalone sales estimate.
• The current commercial problem is lack of demand, not active patent protection.
• No meaningful Orange Book, Paragraph IV, patent litigation, or settlement risk remains.
• Zalcitabine is a small molecule and has no biosimilar exposure.
• Generic manufacture is technically feasible, but modern treatment guidelines make a U.S. commercial launch economically unattractive.
• The drug has no role in current HIV treatment strategy and no material future revenue trajectory.

FAQs About Zalcitabine Market and Patent Status

Is zalcitabine still approved by the FDA?

Zalcitabine was FDA-approved as Hivid, but the product was discontinued in the United States. It is not an active component of current U.S. HIV treatment practice.

Why was Hivid discontinued?

Hivid was discontinued because newer antiretroviral therapies offered better tolerability, simpler dosing, stronger combination utility, and greater clinical value. FDA materials did not identify the discontinuation as a safety or efficacy withdrawal.

Did zalcitabine ever become a blockbuster drug?

There is no public Roche disclosure establishing blockbuster-level standalone revenue for Hivid. Its commercial value was limited by the rapid evolution of HIV therapy and the introduction of competing NRTIs and combination regimens.

Can a pharmaceutical company launch a generic version of zalcitabine?

A company could theoretically pursue a generic or other applicable regulatory pathway, but the commercial opportunity is weak. The primary obstacle is insufficient demand for an older, toxic, three-times-daily antiretroviral.

Does zalcitabine have value in HIV drug-development research?

Its primary value is historical and scientific. Zalcitabine helped establish the clinical utility and limitations of nucleoside reverse transcriptase inhibition, but it is not a current platform for mainstream HIV drug development.

References

1. Hoffmann-La Roche Inc. (2005). Hivid (zalcitabine) tablets prescribing information. U.S. Food and Drug Administration.

2. National Institutes of Health. (n.d.). Zalcitabine. ClinicalInfo.HIV.gov.

3. U.S. Food and Drug Administration. (n.d.-a). Discontinued drug product list. https://www.fda.gov

4. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.

6. Roche Holding Ltd. (1992-2006). Annual reports. Basel, Switzerland: Roche Holding Ltd.